Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 19/20 | 0.52 |
| ▸ | UBA3 | Q8TBC4 | 19/20 | 0.52 |
| ▸ | SAE1 | Q9UBE0 | 15/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 15/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802482 | 1.00 | NAE1 (0.52) | NAE1UBA3SAE1UBA2CA1 | |
| SCHEMBL803312 | 0.90 | NAE1 (0.42) | NAE1UBA3SAE1UBA2CA1 | |
| SCHEMBL17145174 | 0.87 | NAE1 (0.40) | NAE1UBA3SAE1UBA2CA1 | |
| SCHEMBL802365 | 0.82 | UBA1 (0.48) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL803001 | 0.80 | ATG7 (0.38) | NAE1UBA3 | |
| SCHEMBL802373 | 0.79 | NAE1 (0.35) | NAE1UBA3 | |
| SCHEMBL802964 | 0.73 | CA2 (0.39) | NAE1UBA3CA1CA2 | |
| SCHEMBL783073 | 0.70 | NAE1 (0.56) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL12392799 | 0.70 | NAE1 (0.64) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL16155034 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885SAE1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.